Global Metastatic Melanoma Diagnostic Market Research Report 2023

December 2023 | 86 pages | ID: G6BA8D1F85B2EN
QYResearch

Abstracts

Melanoma is one of the serious types of skin cancers that develops from pigment-containing cells called as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Moles, brown spots and growths on the skin are found to be the symptoms associated with the disease. When it spreads to other places in body, it's called metastatic, or advanced. Although in many cases metastatic melanoma can’t be cured, treatments and support can help people live longer and better. Doctors have therapies that have greatly increased survival rates. And researchers are working to find new medications that can do even more.

According to QYResearch’s new survey, global Metastatic Melanoma Diagnostic market is projected to reach US$ 1210.4 million in 2029, increasing from US$ 715 million in 2022, with the CAGR of 7.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metastatic Melanoma Diagnostic market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Metastatic Melanoma Diagnostic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

• Myriad Genetics
• Abbott Laboratories
• Foundation Medicine
• Pathway Genomics Corporation
• Cancer Genetics
• Castle Biosciences
• NeoGenomics
• Dermtech
• Sysmex Inostics

Segment by Type

• BRAF Mutation
• Circulating Tumor Cells (CTCs)
• Immunohistochemistry
• Others

Segment by Application

• Pathology Laboratories
• Hospitals
• Cancer Research Centres
• Others

By Region

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

The Metastatic Melanoma Diagnostic report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies’ Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies’ Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Market Analysis by Type
  1.2.1 Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
  1.2.2 BRAF Mutation
  1.2.3 Circulating Tumor Cells (CTCs)
  1.2.4 Immunohistochemistry
  1.2.5 Others
1.3 Market by Application
  1.3.1 Global Metastatic Melanoma Diagnostic Market Growth by Application: 2018 VS 2022 VS 2029
  1.3.2 Pathology Laboratories
  1.3.3 Hospitals
  1.3.4 Cancer Research Centres
  1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Metastatic Melanoma Diagnostic Market Perspective (2018-2029)
2.2 Metastatic Melanoma Diagnostic Growth Trends by Region
  2.2.1 Global Metastatic Melanoma Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
  2.2.2 Metastatic Melanoma Diagnostic Historic Market Size by Region (2018-2023)
  2.2.3 Metastatic Melanoma Diagnostic Forecasted Market Size by Region (2024-2029)
2.3 Metastatic Melanoma Diagnostic Market Dynamics
  2.3.1 Metastatic Melanoma Diagnostic Industry Trends
  2.3.2 Metastatic Melanoma Diagnostic Market Drivers
  2.3.3 Metastatic Melanoma Diagnostic Market Challenges
  2.3.4 Metastatic Melanoma Diagnostic Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Metastatic Melanoma Diagnostic Players by Revenue
  3.1.1 Global Top Metastatic Melanoma Diagnostic Players by Revenue (2018-2023)
  3.1.2 Global Metastatic Melanoma Diagnostic Revenue Market Share by Players (2018-2023)
3.2 Global Metastatic Melanoma Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metastatic Melanoma Diagnostic Revenue
3.4 Global Metastatic Melanoma Diagnostic Market Concentration Ratio
  3.4.1 Global Metastatic Melanoma Diagnostic Market Concentration Ratio (CR5 and HHI)
  3.4.2 Global Top 10 and Top 5 Companies by Metastatic Melanoma Diagnostic Revenue in 2022
3.5 Metastatic Melanoma Diagnostic Key Players Head office and Area Served
3.6 Key Players Metastatic Melanoma Diagnostic Product Solution and Service
3.7 Date of Enter into Metastatic Melanoma Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans

4 METASTATIC MELANOMA DIAGNOSTIC BREAKDOWN DATA BY TYPE

4.1 Global Metastatic Melanoma Diagnostic Historic Market Size by Type (2018-2023)
4.2 Global Metastatic Melanoma Diagnostic Forecasted Market Size by Type (2024-2029)

5 METASTATIC MELANOMA DIAGNOSTIC BREAKDOWN DATA BY APPLICATION

5.1 Global Metastatic Melanoma Diagnostic Historic Market Size by Application (2018-2023)
5.2 Global Metastatic Melanoma Diagnostic Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Metastatic Melanoma Diagnostic Market Size (2018-2029)
6.2 North America Metastatic Melanoma Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
6.4 North America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada

7 EUROPE

7.1 Europe Metastatic Melanoma Diagnostic Market Size (2018-2029)
7.2 Europe Metastatic Melanoma Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
7.4 Europe Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Metastatic Melanoma Diagnostic Market Size (2018-2029)
8.2 Asia-Pacific Metastatic Melanoma Diagnostic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Metastatic Melanoma Diagnostic Market Size by Region (2018-2023)
8.4 Asia-Pacific Metastatic Melanoma Diagnostic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia

9 LATIN AMERICA

9.1 Latin America Metastatic Melanoma Diagnostic Market Size (2018-2029)
9.2 Latin America Metastatic Melanoma Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
9.4 Latin America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Metastatic Melanoma Diagnostic Market Size (2018-2029)
10.2 Middle East & Africa Metastatic Melanoma Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
10.4 Middle East & Africa Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Myriad Genetics
  11.1.1 Myriad Genetics Company Detail
  11.1.2 Myriad Genetics Business Overview
  11.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Introduction
  11.1.4 Myriad Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.1.5 Myriad Genetics Recent Development
11.2 Abbott Laboratories
  11.2.1 Abbott Laboratories Company Detail
  11.2.2 Abbott Laboratories Business Overview
  11.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Introduction
  11.2.4 Abbott Laboratories Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.2.5 Abbott Laboratories Recent Development
11.3 Foundation Medicine
  11.3.1 Foundation Medicine Company Detail
  11.3.2 Foundation Medicine Business Overview
  11.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Introduction
  11.3.4 Foundation Medicine Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.3.5 Foundation Medicine Recent Development
11.4 Pathway Genomics Corporation
  11.4.1 Pathway Genomics Corporation Company Detail
  11.4.2 Pathway Genomics Corporation Business Overview
  11.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Introduction
  11.4.4 Pathway Genomics Corporation Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.4.5 Pathway Genomics Corporation Recent Development
11.5 Cancer Genetics
  11.5.1 Cancer Genetics Company Detail
  11.5.2 Cancer Genetics Business Overview
  11.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Introduction
  11.5.4 Cancer Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.5.5 Cancer Genetics Recent Development
11.6 Castle Biosciences
  11.6.1 Castle Biosciences Company Detail
  11.6.2 Castle Biosciences Business Overview
  11.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Introduction
  11.6.4 Castle Biosciences Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.6.5 Castle Biosciences Recent Development
11.7 NeoGenomics
  11.7.1 NeoGenomics Company Detail
  11.7.2 NeoGenomics Business Overview
  11.7.3 NeoGenomics Metastatic Melanoma Diagnostic Introduction
  11.7.4 NeoGenomics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.7.5 NeoGenomics Recent Development
11.8 Dermtech
  11.8.1 Dermtech Company Detail
  11.8.2 Dermtech Business Overview
  11.8.3 Dermtech Metastatic Melanoma Diagnostic Introduction
  11.8.4 Dermtech Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.8.5 Dermtech Recent Development
11.9 Sysmex Inostics
  11.9.1 Sysmex Inostics Company Detail
  11.9.2 Sysmex Inostics Business Overview
  11.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Introduction
  11.9.4 Sysmex Inostics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
  11.9.5 Sysmex Inostics Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS


13 APPENDIX

13.1 Research Methodology
  13.1.1 Methodology/Research Approach
  13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of BRAF Mutation
Table 3. Key Players of Circulating Tumor Cells (CTCs)
Table 4. Key Players of Immunohistochemistry
Table 5. Key Players of Others
Table 6. Global Metastatic Melanoma Diagnostic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Metastatic Melanoma Diagnostic Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Metastatic Melanoma Diagnostic Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Metastatic Melanoma Diagnostic Market Share by Region (2018-2023)
Table 10. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Metastatic Melanoma Diagnostic Market Share by Region (2024-2029)
Table 12. Metastatic Melanoma Diagnostic Market Trends
Table 13. Metastatic Melanoma Diagnostic Market Drivers
Table 14. Metastatic Melanoma Diagnostic Market Challenges
Table 15. Metastatic Melanoma Diagnostic Market Restraints
Table 16. Global Metastatic Melanoma Diagnostic Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Metastatic Melanoma Diagnostic Market Share by Players (2018-2023)
Table 18. Global Top Metastatic Melanoma Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Diagnostic as of 2022)
Table 19. Ranking of Global Top Metastatic Melanoma Diagnostic Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Metastatic Melanoma Diagnostic Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Metastatic Melanoma Diagnostic Product Solution and Service
Table 23. Date of Enter into Metastatic Melanoma Diagnostic Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type (2018-2023)
Table 27. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type (2024-2029)
Table 29. Global Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Metastatic Melanoma Diagnostic Revenue Market Share by Application (2018-2023)
Table 31. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Metastatic Melanoma Diagnostic Revenue Market Share by Application (2024-2029)
Table 33. North America Metastatic Melanoma Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Metastatic Melanoma Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Metastatic Melanoma Diagnostic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Metastatic Melanoma Diagnostic Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Metastatic Melanoma Diagnostic Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Metastatic Melanoma Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Metastatic Melanoma Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 48. Myriad Genetics Company Detail
Table 49. Myriad Genetics Business Overview
Table 50. Myriad Genetics Metastatic Melanoma Diagnostic Product
Table 51. Myriad Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 52. Myriad Genetics Recent Development
Table 53. Abbott Laboratories Company Detail
Table 54. Abbott Laboratories Business Overview
Table 55. Abbott Laboratories Metastatic Melanoma Diagnostic Product
Table 56. Abbott Laboratories Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 57. Abbott Laboratories Recent Development
Table 58. Foundation Medicine Company Detail
Table 59. Foundation Medicine Business Overview
Table 60. Foundation Medicine Metastatic Melanoma Diagnostic Product
Table 61. Foundation Medicine Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 62. Foundation Medicine Recent Development
Table 63. Pathway Genomics Corporation Company Detail
Table 64. Pathway Genomics Corporation Business Overview
Table 65. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product
Table 66. Pathway Genomics Corporation Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 67. Pathway Genomics Corporation Recent Development
Table 68. Cancer Genetics Company Detail
Table 69. Cancer Genetics Business Overview
Table 70. Cancer Genetics Metastatic Melanoma Diagnostic Product
Table 71. Cancer Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 72. Cancer Genetics Recent Development
Table 73. Castle Biosciences Company Detail
Table 74. Castle Biosciences Business Overview
Table 75. Castle Biosciences Metastatic Melanoma Diagnostic Product
Table 76. Castle Biosciences Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 77. Castle Biosciences Recent Development
Table 78. NeoGenomics Company Detail
Table 79. NeoGenomics Business Overview
Table 80. NeoGenomics Metastatic Melanoma Diagnostic Product
Table 81. NeoGenomics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 82. NeoGenomics Recent Development
Table 83. Dermtech Company Detail
Table 84. Dermtech Business Overview
Table 85. Dermtech Metastatic Melanoma Diagnostic Product
Table 86. Dermtech Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 87. Dermtech Recent Development
Table 88. Sysmex Inostics Company Detail
Table 89. Sysmex Inostics Business Overview
Table 90. Sysmex Inostics Metastatic Melanoma Diagnostic Product
Table 91. Sysmex Inostics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 92. Sysmex Inostics Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Metastatic Melanoma Diagnostic Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Metastatic Melanoma Diagnostic Market Share by Type: 2022 VS 2029
Figure 3. BRAF Mutation Features
Figure 4. Circulating Tumor Cells (CTCs) Features
Figure 5. Immunohistochemistry Features
Figure 6. Others Features
Figure 7. Global Metastatic Melanoma Diagnostic Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Metastatic Melanoma Diagnostic Market Share by Application: 2022 VS 2029
Figure 9. Pathology Laboratories Case Studies
Figure 10. Hospitals Case Studies
Figure 11. Cancer Research Centres Case Studies
Figure 12. Others Case Studies
Figure 13. Metastatic Melanoma Diagnostic Report Years Considered
Figure 14. Global Metastatic Melanoma Diagnostic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Metastatic Melanoma Diagnostic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Metastatic Melanoma Diagnostic Market Share by Region: 2022 VS 2029
Figure 17. Global Metastatic Melanoma Diagnostic Market Share by Players in 2022
Figure 18. Global Top Metastatic Melanoma Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Diagnostic as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Metastatic Melanoma Diagnostic Revenue in 2022
Figure 20. North America Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 22. United States Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 26. Germany Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Metastatic Melanoma Diagnostic Market Share by Region (2018-2029)
Figure 34. China Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 42. Mexico Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 46. Turkey Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Myriad Genetics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 49. Abbott Laboratories Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 50. Foundation Medicine Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 51. Pathway Genomics Corporation Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 52. Cancer Genetics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 53. Castle Biosciences Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 54. NeoGenomics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 55. Dermtech Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 56. Sysmex Inostics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed